A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data

PADOVA has successfully recruited an early-stage PD population to test the effect of prasinezumab when added to background SOC.